Advancing Precision IBD Care Through Biomarker-Driven Insights and Translational Innovation

• Identify and validate biomarkers that stratify patient subgroups and predict therapeutic response across diverse clinical studies
• Integrate translational biomarker data from clinical and real-world models to inform disease progression and treatment outcomes
• Accelerate precision therapy development by linking biomarker discovery to targeted intervention strategies in ulcerative colitis and Crohn’s disease

Speakers:

Dongdong Lin

Statistical biomarker leader

Sanofi